National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Tralokinumab (Adtralza®). HTA ID: 21028

Tralokinumab (Adtralza®) is indicated for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 29/06/2021
Rapid review completed 29/07/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that tralokinumab should not be considered for reimbursement at the submitted price.*


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.